First-in-human trial of Dz13 for nodular basal-cell carcinoma

The Lancet

Volumn 381, Issue 9880, 2013, Pages 1797-1798

  Grassi, Gabriele ^a,b   Grassi, Mario ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNAZYME DZ13; LIPOSOME; MESSENGER RNA; NUCLEIC ACID BASE; PROTEIN C JUN; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

BASAL CELL CARCINOMA; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; SKIN CANCER;

EID: 84878110171     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60633-9     Document Type: Note

References (14)

1. Grassi M, Cavallaro G, Scirè S, et al. Current strategies to improve the efficacy and the delivery of nucleic acid based drugs. Curr Signal Transduct Ther 2010; 5: 92-120.
2. Santoro SW, Joyce GF A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 1997; 94: 4262-66.
3. Achenbach JC, Chiuman W, Cruz R., Li Y. DNAzymes: from creation in vitro to application in vivo. Curr Pharm Biotechnol 2004; 5: 321-36.
4. Luo X, Cai H, Ni J., et al c-Jun DNAzymes inhibit myocardial inflammation, ROS generation, infarct size, and improve cardiac function after ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 2009; 29: 1836-42.
5. Zhang L, Gasper WJ, Stass S.A., Ioffe OB, Davis MA, Mixson AJ Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res 2002; 62: 5463-69.
6. Cairns MJ, Hopkins TM, Witherington C, Wang L., Sun LQ Target site selection for an RNA-cleaving catalytic DNA. Nat Biotechnol 1999; 17: 480-86.
7. Fahmy RG, Waldman A, Zhang G., et al Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. Nat Biotechnol 2006; 24: 856-63.
8. Fahmy RG, Dass CR, Sun L.Q., Chesterman CN, Khachigian LM Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 2003; 9: 1026-32.
9. Santiago FS, Lowe HC, Kavurma M.M., et al New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat Med 1999; 5: 1264-69.
10. Cho E-A, Moloney F.J., Cai H., et al Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). Lancet 2013; published online May 7. http://dx.doi.org/10.1016/S0140-6736(12)62166-7.
11. Cai H, Santiago FS, Prado-Lourenco L, et al DNAzyme targeting c-jun suppresses skin cancer growth. Sci Transl Med 2012; 4: 139ra82.
12. Jin JY, Ke H, Hall R.P., Zhang JY c-Jun promotes whereas JunB inhibits epidermal neoplasia. J Invest Dermatol 2011; 131: 1149-58.
13. Grassi M, Grassi G, Lapasin R., Colombo I. Understanding drug release and absorption mechanisms: a physical and mathematical approach. Boca Raton, FL: CRC Press, 2006.
14. Phillips MA, Gran ML, Peppas NA Targeted nanodelivery of drugs and diagnostics. Nano Today 2010; 5: 143-59.